Innovate Pharmaceuticals has launched what it claims is the world’s first shelf-stable liquid aspirin, and says it is on the look-out for a licensing partner for the “$500m” market.
Drug companies still outsource to cut costs but environmental concerns and therefore contractors’ green credentials are increasingly important say industry experts.
Increasing QbD needs and a range of technical service centres have driven up the prices of Evonik’s drug delivery excipient portfolio, the company says.
Mayne Pharma has started adding contract manufacturing capacity at its site in North Carolina in an project that will also see it consolidate US distribution operations.
Lonza has published a guide to clinical-grade induced pluripotent stem cell (IPSC) manufacture, addressing concerns around the derivation of cellular materials.
Cobra Biologics, a Swedish contract development and manufacturing organisation, has launched a project to improve scale-up of biologics with the University of Manchester, UK.
Hangzhou CMO Ausia BioTech has partnered with New Mexico-based PaizaBio to market its manufacturing services to Western drugmakers interested in the Chinese sterile injectables market.
Standard & Poor has assigned a ‘stable’ rating to Greatbatch after the contract manufacturer secured $1.5bn to buy fellow medical devicemaker Lake Region Medical.
Novo Nordisk building its first manufacturing facility in Middle-East
Danish biotech Bavarian Nordic has signed a $9m contract from Johnson & Johnson to improve stability of their joint Ebola vaccine. After options and milestone awards, payment could total $33m.
Trial supplies of a radio-immunotherapy drug made by Areva Med in compliance with GMP are stable five years after they were produced according to the results of new analysis.
Manufacturing backlog at Avid Bioservices has reached $42m as the firm books up space at a new facility currently undergoing its first internal pilot run.
Vladimir Putin says support from Russian business community is needed to help achieve the domestic drug manufacturing goals set out in his Pharma 2020 policy.
Sanofi’s decision to stop manufacturing an anti-venom will contribute to “needless death and disability” for snake bite victims, according to Médecins Sans Frontières.
Hospira’s injectables contracting business will operate alongside Pfizer’s CentreSource services unit following the completion of the $17bn takeover deal last week.
Investments in technologies and capabilities are reaping rewards says Catalent which will continue placing “disproportionate emphasis” on its biologics business.
An Indian TB drugmaker has been hit with a WHO Notice of Concern but an independent audit carried out by its customer Svizera Europe disputes the GMP violations raised.
Sanofi wants to expand its inhalable drug production site in Cheshire, UK to increase capacity for both its own brand drug production operations and its contract manufacturing business.
Boehringer Ingelheim has licensed a microbial expression technology from Vectron Biosolutions for use with its own molecules and for customers through its CMO business.
The National Institute of Pharmaceutical Education and Research (NIPER) in India has created and licensed technology for producing nano-crystal based medicines that it says will cut drug costs.
Army training is ideal preparation for a biopharma career according to the US National Center for Therapeutics Manufacturing, which is seeking former military personnel interested in learning about bioprocessing.
Shire will use contractors to increase production of Cinryze, the half billion dollar-a-year Hereditary Angioedema (HAE) drug it bought with ViroPharma in 2014.
Pharma firms developing inhalable drugs often fail to test that their formulations are compatible with their intended delivery devices early enough according to the Intertek team behind research stressing the benefits of early assessment.
